317 related articles for article (PubMed ID: 34177799)
21. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR
Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695
[TBL] [Abstract][Full Text] [Related]
22. [Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs].
Kamyshova ES; Bobkova IN; Sekacheva MI
Ter Arkh; 2021 Jun; 93(6):649-660. PubMed ID: 36286830
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
24. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
König D; Läubli H
Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
[TBL] [Abstract][Full Text] [Related]
25. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
26. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
27. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
Sobol I; Chen CL; Mahmood SS; Borczuk AC
Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T; Yamaguchi Y
Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
[TBL] [Abstract][Full Text] [Related]
29. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
30. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
31. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
Inaba H; Ariyasu H; Iwakura H; Kurimoto C; Takeshima K; Morita S; Furuta H; Hotomi M; Akamizu T
Endocr J; 2021 Feb; 68(2):231-241. PubMed ID: 33012745
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
34. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
35. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
36. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis.
Zhao Y; Hao C; Li M; Qu Y; Guo Y; Deng X; Si H; Yao W
Biomed Pharmacother; 2022 Apr; 148():112768. PubMed ID: 35247717
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]